TransMedics Group, Inc. TMDX Product — Clinical Trial Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TransMedics Group, Inc. in its filing.
Tagged under the XBRL concept tmdx:ClinicalTrialExpense.
The official record: TransMedics Group, Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about TransMedics Group, Inc.'s product — clinical trial expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TransMedics Group, Inc.'s product — clinical trial expense?
- TransMedics Group, Inc. (TMDX) reported product — clinical trial expense of $0 in Q4 2025.
- How has TransMedics Group, Inc.'s product — clinical trial expense changed year-over-year?
- TransMedics Group, Inc.'s product — clinical trial expense increased by 100.0% year-over-year, from -$46.5K to $0.
- What is the long-term trend for TransMedics Group, Inc.'s product — clinical trial expense?
- Over 4 years (2021 to 2025), TransMedics Group, Inc.'s product — clinical trial expense has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.
- What does product — clinical trial expense mean?
- This metric tracks the specific costs associated with conducting clinical research, trials, and regulatory validation studies for products within a business segment. These expenditures are critical for demonstrating safety and efficacy to regulatory bodies to support market authorization or label expansion. High investment in this area indicates a commitment to long-term product innovation and the development of new clinical indications.